For instance, some individuals think they will stop taking them once theyve lost weight while others are only using them cosmetically and not for management of a chronic disease. Call for more research In a new JAMA Viewpoint opinion piece, Khan and others call for more research to understand the causes of this discontinuation and the development of clinical and policy interventions to support long-term use
513,522 In a mouse model induced with NASH-related HCC, treatment with liraglutide (a type of GLP-1RA) was shown to prevent the progression of hepatocellular carcinoma
The most common adverse events were gastrointestinal and generally mild to moderate
10.1001/jama.298.3.309 [DOI] [PubMed] [Google Scholar] 233.Do R, Willer CJ, Schmidt EM, Sengupta S, Gao C, Peloso GM, et al
These drugs may not be as effective as FDA-approved medications and may contain contaminants
Cross-disciplinary cardiovascular and psychiatric recommendations: a systematic review of clinical guidelines